Novo Nordisk A/S (NYSE:NVO) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Novo Nordisk A/S (NYSE:NVO) posted its quarterly earnings results on Wednesday. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03, Zacks reports. Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 86.32%. Novo Nordisk A/S updated its FY 2025 guidance to EPS.

Novo Nordisk A/S Stock Up 4.9 %

Novo Nordisk A/S stock traded up $4.05 during mid-day trading on Wednesday, reaching $86.67. 9,056,927 shares of the company’s stock were exchanged, compared to its average volume of 9,280,718. The company has a fifty day moving average of $92.65 and a 200-day moving average of $112.19. The company has a market cap of $388.95 billion, a P/E ratio of 28.05, a P/E/G ratio of 0.93 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research reports. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.